Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Collider: Innovation & Asymmetric Learning in Pharma artwork

IDEA Collider | Kabir Nath

Aug 26, 202152 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Kabir Nath is President & CEO, Otsuka North America Pharmaceutical Business Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond cultural and linguistic differences to bring new concepts and ideas to life, forging stronger partnerships rooted in diverse experiences. For Kabir, leadership is not about having all the answers, rather, it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the patients and families they serve. In his nearly 30 years of broad international biopharmaceutical and medical-device experience, Kabir has shaped strategy to deliver results in complex, challenging business environments at the country, regional, and global level. Otsuka, with its unique blend of Japanese and American cultures, is the place where Kabir puts his purpose into practice daily. Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business. Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.

    Oct 22, 202642 minAudio

    In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO...

    Credit the people on this episode

  2. AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould.

    Oct 7, 202641 minAudio

    Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at...

    Credit the people on this episode

  3. The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II

    Sep 14, 202636 minAudio

    Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer...

    Credit the people on this episode

  4. Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy

    Jul 16, 202649 minAudio

    Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30...

    Credit the people on this episode

  5. The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.

    Jul 1, 202650 minAudio

    Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly...

    Credit the people on this episode